Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized Double-Blind Pilot Study of Memantine Augmentation in Antidepressant Nonresponders or Incomplete Responders

To see complete record on, please visit this link

Id: NCT00344682

Organisation Name: University of Massachusetts, Worcester

Overal Status: Completed

Start Date: June 2006

Last Update: July 11, 2018

Lead Sponsor: University of Massachusetts, Worcester

Brief Summary: This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.

  • Depressive Disorder

Total execution time in seconds: 0.21336603164673